<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

SKI 606 - Bosutinib

產(chǎn)品貨號(hào)

Axon 1407 CAS [380843-75-4] MF C26H29Cl2N5O3MW 530.45 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description A tyrosine kinase inhibitor (TKI), targeting dual Bcr-Abl and Src; effective drug for chronic myelogenous leukemia (CML) or acute lymphoid leukemia (ALL) References Certificates Categories Extra info A Vultur et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol. Cancer Ther. 2008, 7(5), 1185–1194.? ? W. A. Messersmith et al.Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors. J. Clinical Oncol. 2007, 25 (18S), 3552.? ? JM Goldman, JV Melo.?BCR-ABL in Chronic Myelogenous Leukemia - How Does It Work??Acta Haematol.?2008, 119, 212-217.? Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology BCR-ABL SRC Oncogene Fusion Proteins EC 2.7.10.1 Pfizer Licensed Products Bcr-Abl and Src tyrosine kinase inhibitor Chemical name 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrile Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [380843-75-4] Order Size Unit Price Stock 5 mg €75.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

SKI 606 - Bosutinib

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 1407

CAS [380843-75-4]

MF C26H29Cl2N5O3
MW 530.45

Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO

SKI 606

Description

A tyrosine kinase inhibitor (TKI), targeting dual Bcr-Abl and Src; effective drug for chronic myelogenous leukemia (CML) or acute lymphoid leukemia (ALL)

A Vultur et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol. Cancer Ther. 2008, 7(5), 1185–1194.?

W. A. Messersmith et al.Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors. J. Clinical Oncol. 2007, 25 (18S), 3552.?

JM Goldman, JV Melo.?BCR-ABL in Chronic Myelogenous Leukemia - How Does It Work??Acta Haematol.?2008, 119, 212-217.?

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology BCR-ABL SRC Oncogene Fusion Proteins EC 2.7.10.1 Pfizer Licensed Products

Bcr-Abl and Src tyrosine kinase inhibitor

Chemical name

4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrile

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[380843-75-4]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>